Search results
Results from the WOW.Com Content Network
Pomalidomide, sold under the brand names Pomalyst and Imnovid, [7] [8] is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. [ 7 ] Pomalidomide was approved for medical use in the United States in February 2013, [ 10 ] and in the European Union in August 2013. [ 8 ]
First reported in 2001, pomalidomide was noted to directly inhibit myeloma cell proliferation and thus inhibiting MM both on the tumor and vascular compartments. [13] This dual activity of pomalidomide makes it more efficacious than thalidomide both in vitro and in vivo. [14]
Oral Anti-Cancer Therapy Pomalidomide Now Approved by European Commission as Treatment for Patients with Relapsed/Refractory Multiple Myeloma - a Rare Form of Blood Cancer BOUDRY, Switzerland ...
51185 58799 Ensembl ENSG00000113851 ENSMUSG00000005362 UniProt Q96SW2 Q8C7D2 RefSeq (mRNA) NM_001173482 NM_016302 NM_021449 NM_175357 RefSeq (protein) NP_001166953 NP_057386 NP_067424 NP_780566 Location (UCSC) Chr 3: 3.14 – 3.18 Mb Chr 6: 106.76 – 106.78 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Cereblon is a protein that in humans is encoded by the CRBN gene. The gene that ...
Celgene Corporation Announces Pomalidomide Will Be Reviewed at FDA Advisory Committee ODAC will discuss pomalidomide NDA for the treatment of patients with relapsed and refractory multiple myeloma ...
Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma. [6] [4]The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell), infusion reactions, pneumonia (infection of the lungs), upper respiratory tract infection (such as nose and throat infections), diarrhoea and bronchitis ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
(Reuters) -The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's ...